期刊
CHEMICAL COMMUNICATIONS
卷 50, 期 36, 页码 4659-4673出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/c4cc00660g
关键词
-
资金
- Camille & Henry Dreyfus Foundation
- National Center for Research Resources [5P20RR016463-12]
- National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GM103423-12]
- NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016463] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103423] Funding Source: NIH RePORTER
A substantial obstacle to the existing treatment of bacterial diseases is the lack of specific probes that can be used to diagnose and treat pathogenic bacteria in a selective manner while leaving the microbiome largely intact. To tackle this problem, there is an urgent need to develop pathogen-specific therapeutics and diagnostics. Here, we describe recent evidence that indicates distinctive glycans found exclusively on pathogenic bacteria could form the basis of targeted therapeutic and diagnostic strategies. In particular, we highlight the use of metabolic oligosaccharide engineering to covalently deliver therapeutics and imaging agents to bacterial glycans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据